Oxicam Explained
Oxicam is a class of non-steroidal anti-inflammatory drugs (NSAIDs),[1] meaning that they have anti-inflammatory, analgesic, and antipyretic therapeutic effects. Oxicams bind closely to plasma proteins.[2] Most oxicams are unselective inhibitors of the cyclooxygenase (COX) enzymes. The exception is meloxicam with a slight (10:1) preference for COX-2, which, however, is only clinically relevant at low doses.[3]
The most popular drug of the oxicam class is piroxicam.[2] Other examples include: ampiroxicam, droxicam, pivoxicam, tenoxicam, lornoxicam,[2] and meloxicam.
Isoxicam has been suspended as a result of fatal skin reactions.[2]
Chemistry
The physico-chemical characteristics of these molecules vary greatly depending upon the environment.[4]
In contrast to most other NSAIDs, oxicams are not carboxylic acids. They are tautomeric, and can exist as a number of tautomers (keto-enol tautomerism), here exemplified by piroxicam:[1]
Side effects
The use of NSAIDs can, rarely, trigger severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).[5] Epidemiologic studies and reviews have reported that, among NSAIDs, the oxicam derivatives (e.g., piroxicam, tenoxicam, meloxicam) are associated with a comparatively higher risk of SJS/TEN, particularly early after starting treatment, although the absolute risk remains low.[6] [7]
Isoxicam was withdrawn/suspended from marketing after reports of fatal skin reactions.[8]
References
- Ivanova D, Deneva V, Nedeltcheva D, Kamounah FS, Gergov G, Hansen PE, Kawauchi S, Antonov L. March 2015. Tautomeric transformations of piroxicam in solution: a combined experimental and theoretical study. RSC Advances. Royal Society of Chemistry. England, UK. 5. 31852–31860. 40. 10.1039/c5ra03653d. 2015RSCAd...531852I . free.
- Olkkola KT, Brunetto AV, Mattila MJ. February 1994. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clinical Pharmacokinetics. 26. 2. 107–20. 8162655. 10.2165/00003088-199426020-00004. 13300943 .
- Book: Mutschler, Ernst. Gerd Geisslinger. Heyo K. Kroemer. Monika Schäfer-Korting. 2001. Mutschler Arzneimittelwirkungen: Lehrbuch der Pharmakologie und Toxikologie; mit einführenden Kapiteln in die Anatomie, Physiologie und Pathophysiologie. German. Mutster medicine effects: Textbook of pharmacology and toxicology; with introductory chapters in anatomy, physiology and pathophysiology. Wissenschaftliche Verlagsgesellschaft. Stuttgart, Germany. 8. 233. 3-8047-1763-2. 12928661M. 48723029.
- Banerjee R, Chakraborty H, Sarkar M. April 2003. Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. Elsevier. 59. 6. 1213–22. 2003AcSpA..59.1213B. 10.1016/S1386-1425(02)00300-1. 12659890.
- Ward . Kristina E. . Archambault . Raoul . Mersfelder . Tracey L. . 2010-02-01 . Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature . American Journal of Health-System Pharmacy . 67 . 3 . 206–213 . 10.2146/ajhp080603 . 1535-2900 . 20101062.
- Mockenhaupt . Maja . Kelly . Judith Parsells . Kaufman . David . Stern . Robert S. . SCAR Study Group . The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective . The Journal of Rheumatology . 30 . 10 . 2234–2240 . 0315-162X . 14528522.
- Harr . T. . French . L. E. . 2010 . Toxic epidermal necrolysis and Stevens-Johnson syndrome . Orphanet Journal of Rare Diseases . 5 . 39 . 10.1186/1750-1172-5-39 . free . 3021447 . 21162721.
- Olkkola . K. T. . Brunetto . A. V. . Mattila . M. J. . 1994 . Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents . Clinical Pharmacokinetics . 26 . 2 . 107–120 . 10.2165/00003088-199426020-00004 . 8162655.